Learning impairment following intracerebral administration of the HIV envelope protein gp120 or a VIP antagonist.
about
A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growthSelect cognitive deficits in vasoactive intestinal peptide deficient mice.Neuroprotective strategy for Alzheimer disease: intranasal administration of a fatty neuropeptide.A novel signaling molecule for neuropeptide action: activity-dependent neuroprotective protein.Preclinical psychopharmacology of AIDS-associated dementia: lessons to be learned from the cognitive psychopharmacology of other dementias.VIP enhances phagocytosis of fibrillar beta-amyloid by microglia and attenuates amyloid deposition in the brain of APP/PS1 miceHuman immunodeficiency virus coat protein gp120 inhibits the beta-adrenergic regulation of astroglial and microglial functions.In vitro and animal models of human immunodeficiency virus infection of the central nervous systemTranslational spatial task and its relationship to HIV-associated neurocognitive disorders and apolipoprotein E in HIV-seropositive women.The HIV-1 transgenic rat model of neuroHIV.Expression of HIV-Tat protein is associated with learning and memory deficits in the mouse.Neurotoxic profiles of HIV, psychostimulant drugs of abuse, and their concerted effect on the brain: current status of dopamine system vulnerability in NeuroAIDSTargeting the glutamatergic system for the treatment of HIV-associated neurocognitive disordersIn vivo microdialysis in awake, freely moving rats demonstrates HIV-1 Tat-induced alterations in dopamine transmissionInhibition of murine embryonic growth by human immunodeficiency virus envelope protein and its prevention by vasoactive intestinal peptide and activity-dependent neurotrophic factor.Intranasal therapeutic strategies for management of Alzheimer's disease.Expression of human immunodeficiency virus type 1 in the nervous system of transgenic mice leads to neurological disease.HIV-1 Glycoprotein 120 Enhancement of N-Methyl-D-Aspartate NMDA Receptor-Mediated Excitatory Postsynaptic Currents: Implications for HIV-1-Associated Neural Injury.Neuropeptide GPCRs in neuroendocrinology: the case of activity-dependent neuroprotective protein (ADNP)Neuropeptides and neuronal survival: neuroprotective strategy for Alzheimer's disease.Neuronal PINCH is regulated by TNF-α and is required for neurite extension.Intracerebroventricular infusions of gp120 inhibit weight gain and induce atrophy in the hippocampus and neostriatum without affecting cognition.HIV-1 gp120 Effects on Signal Transduction Processes and Cytokines: Increased src-Family Protein Tyrosine Kinase Activity.Endogenous inhibition of hippocampal LTD and depotentiation by vasoactive intestinal peptide VPAC1 receptors.Multiple actions of a hybrid PACAP antagonist: neuronal cell killing and inhibition of sperm motility.Characterization of lectin-mediated brain uptake of HIV-1 GP120.Steroid Regulation of Vasoactive Intestinal Peptide (VIP).Protection against developmental retardation in apolipoprotein E-deficient mice by a fatty neuropeptide: implications for early treatment of Alzheimer's disease.Lateralized hippocampal effects of vasoactive intestinal peptide on learning and memory in rats in a model of depression.Age-related behavioural deficits in transgenic mice expressing the HIV-1 coat protein gp120.Verification of the interaction between peptide T and CD4 using surface plasmon resonance.HIV-1 gp120 glycoprotein affects the astrocyte control of extracellular glutamate by both inhibiting the uptake and stimulating the release of the amino acid
P2860
Q24315687-9797BFEC-A312-4E62-9230-0B94DB3C1E13Q33350694-F7B4463A-1E08-42CD-B6E9-05C1849E4252Q33628181-ED2BC966-54AE-40F7-8444-F934974102C5Q33838456-2107ECB1-1EA8-4893-B866-4CF394EC6B56Q34098757-D3795563-5904-48C7-B20A-D5B486E4FCF6Q34157261-529D0A0F-A412-4D9D-9C10-37B909061E18Q34355331-1B94250E-CDBC-40B2-8B32-B52B977F283FQ34621972-DC7C76B8-B3E5-404C-8F87-EF98D43A9E1AQ36429120-275DE134-BD67-4B6D-A65D-A87C6ECF80B5Q36578522-378E3549-9A47-4EE5-A9ED-B4ECE64874D4Q36632791-EF39778A-0FB6-4140-8B3A-85FD01B33E11Q36856162-8B27764F-33FF-40FE-ABC5-08D7685E986FQ36868552-247A5C42-3A30-4651-B563-801DF6C2F119Q36991639-C9CEE347-44D6-497D-AFA3-C1FC48D84ACAQ37368552-942644CE-8B28-4A28-831A-F17F4E73BA51Q38176935-C9E5A43B-F2B3-4F62-A04B-5C37D97A0EB4Q40042302-77ECBD8D-B7AE-486F-8AC5-F44D3B43581AQ40412103-392B8712-EB30-4240-BC2A-4113485F67B6Q41110045-CF23E020-0CA7-45BF-BC06-9B9E76A214ECQ41478937-C034C18A-DA75-4C35-ABDC-C332C63BB001Q42745285-E1A3FFE0-C857-40D5-832F-BE2A22001EB2Q47327838-9E379335-88A8-4228-9ADD-FDFC4AEB655FQ47902692-CA27E78E-C0F4-4F04-BDFE-768FF177FA08Q48272166-4359CDE0-8AFC-4578-93E5-BE10D18CCF26Q48295145-6C0DDD36-6A15-4469-A6A6-39C2E7635B44Q48346920-E5D93E37-2853-4E69-B745-E101F0CA919FQ48367482-5C55C0AD-E303-478A-9E2C-8BA08A48AF39Q48627726-239FCB88-84BE-4AF4-ABDB-814AE397C515Q48786854-C7F6EAB2-75A5-4E3D-BDD4-96021993C2CFQ52030469-8D0CCD25-F2B7-44C2-80A7-9FA9BEA5FA12Q52388857-0A105031-253E-483F-8502-A6BE1071DDF0Q57732215-C850DC9A-AB86-4AAE-AEF0-EE13E67B1AF3
P2860
Learning impairment following intracerebral administration of the HIV envelope protein gp120 or a VIP antagonist.
description
1992 nî lūn-bûn
@nan
1992 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Learning impairment following ...... ein gp120 or a VIP antagonist.
@ast
Learning impairment following ...... ein gp120 or a VIP antagonist.
@en
Learning impairment following ...... ein gp120 or a VIP antagonist.
@nl
type
label
Learning impairment following ...... ein gp120 or a VIP antagonist.
@ast
Learning impairment following ...... ein gp120 or a VIP antagonist.
@en
Learning impairment following ...... ein gp120 or a VIP antagonist.
@nl
prefLabel
Learning impairment following ...... ein gp120 or a VIP antagonist.
@ast
Learning impairment following ...... ein gp120 or a VIP antagonist.
@en
Learning impairment following ...... ein gp120 or a VIP antagonist.
@nl
P2093
P1433
P1476
Learning impairment following ...... ein gp120 or a VIP antagonist.
@en
P2093
P356
10.1016/0006-8993(92)90562-N
P407
P577
1992-01-01T00:00:00Z